Association between XPC Lys939Gln(A/C) gene polymorphism and the susceptibility of gastric cancer: a Metaanalysis

doi:10.3760/cma.j.issn.1673-422X.2016.08.009

Abstract

Abstract: Objective To explore the association between Xeroderma pigmentosum complementation C group (XPC) Lys939Gln (A/C) gene polymorphism and the susceptibility of gastric cancer. Methods By searching PubMed, Cochrane Library, Elsevier, SpringerVerlag, China National Knowledge Infrastructure, Chinese Biomedical Literature Data, VIP Database and Wanfang Database, all eligible casecontrol studies published up to September 2015 were selected and the quality of each article was valuated by two reviewers independently according to the inclusion and exclusion criteria. Meta-analysis was performed by using STATA 12.0 software. Odds ratio (OR) and 95% confidence interval (CI) were calculated. The text was estimated for the subgroup analysis, sensitivity analysis and publication bias test. Results A total of 7 casecontrol studies were included, including 2 336 cases with gastric cancer and 3 502 controls. The Metaanalysis showed that compared with the allele A, the allele C increased the risk of gastric cancer (OR=1.09, 95%CI: 1.01-1.18, Z=2.12, P=0.034); compared to the genotype AA, the homozygous model (CC) and dominant model (CC+AC) also increased the risk of gastric cancer (CC vs.AA: OR=1.19, 95%CI: 1.00-1.42, Z=2.00, P=0.046; CC+AC vs.AA: OR=1.12, 95%CI: 1.00-1.25, Z=2.03, P=0.042). The Meta-analysis showed the statistical significance between XPC Lys939Gln (A/C) gene polymorphism and the gastric cancer risk in subgroup of Asian people (C vs.A: OR=1.10, 95%CI: 1.01-1.20, Z=2.28, P=0.023; CC vs.AA: OR=1.21, 95%CI: 1.01-1.46, Z=2.02, P=0.043; CC+AC vs.AA: OR=1.13, 95%CI: 1.01-1.27, Z=2.11, P=0.035) and the source of community in the control group (C vs.A: OR=1.11, 95%CI: 1.01-1.21, Z=2.25, P=0.024; CC vs.AA: OR=1.23, 95%CI: 1.02-1.50, Z=2.12, P=0.034). Conclusion XPC Lys939Gln(A/C) gene polymorphism may be associated with the susceptibility of gastric cancer, and genotype CC, CC+AC and allele C can increase the risk of gastric cancer.

Key words: Stomach neoplasms, Polymorphism, genetic, Polymorphism, single nucleotide, Meta-analysis, Xeroderma pigmentosum complementation C group

Cui Jing, Tan Hui, Jiang Lei, Yuan Wenzhen, Guan Quanlin. Association between XPC Lys939Gln(A/C) gene polymorphism and the susceptibility of gastric cancer: a Metaanalysis[J]. Journal of International Oncology, 2016, 43(8): 597-602.

References

［1］ Fock KM. Review article: the epidemiology and prevention of gastric cancer［J］. Aliment Pharmacol Ther, 2014, 40(3): 250-260. DOI: 10.1111/apt.12814. ［2］ Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015［J］. CA Cancer J Clin, 2015, 65(1): 5-29. DOI: 10.3322/caac.21254. ［3］邹文斌, 吴浩, 蔡全才，等. 胃癌危险因素研究进展［J］. 中国实用内科杂志, 2014, 34(4): 415-420. ［4］吴雪铭, 马韵, 龙喜带. DNA修复基因XPC研究进展［J］. 右江民族医学院学报, 2009, 31(5): 876-878. DOI: 10.3969/j.issn.1001-.2009.05.088. ［5］李龙嫚, 余红平. XPC、XPG基因单核苷酸多态性与肿瘤遗传易感性关系的研究进展［J］. 医学综述, 2010, 16(6): 801-804. ［6］ Thoma BS, Vasquez KM. Critical DNA damage recognition functions of XPC-hHR23B and XPA-RPA in nucleotide excision repair［J］. Mol Carcinog, 2003, 38(1): 1-13. ［7］ Sugasawa K, Ng JM, Masutani C, et al. Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair［J］. Mol Cell, 1998, 2(2): 223-232. ［8］ Vodicka P, Kumar R, Stetina R, et al. Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and singlestrand breaks in DNA［J］. Carcinogenesis, 2004, 25(5): 757-763. ［9］陈泽鑫, 刘慧, 潘益峰, 等. 试验性和观察性研究相关医学文献质量评价方法［J］. 中国循证医学杂志, 2011, 11(11): 1229-1236. ［10］李丹萍, 侯慧, 徐昌青, 等. xpc基因多态性与胃癌发生风险的关系［J］. 山东医药, 2014, 54(13): 2426. DOI: 10.3969/j.issn.1002-266X.2014.13.009. ［11］贺静. 核苷酸剪切修复基因单核苷酸多态性与胃癌遗传易感性的分子流行病学研究［D］. 上海: 复旦大学, 2013. ［12］ Long XD, Ma Y, Huang YZ, et al. Genetic polymorphisms in DNA repair genes XPC, XPD, and XRCC4, and susceptibility to Helicobacter pylori infection-related gastric antrum adenocarcinoma in Guangxi population, China［J］. Mol Carcinog, 2010, 49(6): 611-618. DOI: 10.1002/mc.20630. ［13］ Ye W, Kumar R, Bacova G, et al. The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a populationbased casecontrol study in Sweden［J］. Carcinogenesis, 2006, 27(9): 1835-1841. ［14］ Engin A, Karahalil B, Engin A, et al. DNA repair enzyme polymorphisms and oxidative stress in a Turkish population with gastric carcinoma［J］. Mol Biol Rep, 2011, 38(8): 5379-5386. DOI: 10.1007/s11033-011-0690-9. ［15］ Dong Z, Guo W, Zhou R, et al. Polymorphisms of the DNA repair gene XPA and XPC and its correlation with gastric cardiac adenocarcinoma in a high incidence population in North China［J］. J Clin Gastroenterol, 2008, 42(8): 910-915. DOI: 10.1097/MCG.0b013e3180f6262c. ［16］郭剑波. DNA修复基因XPC多态性及单体型与胃癌遗传易感性的关系［D］. 辽宁: 中国医科大学, 2012. ［17］ Ang TL, Fock KM. Clinical epidemiology of gastric cancer［J］. Singapore Med J, 2014, 55(12): 621-628. ［18］ Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review［J］. J Natl Cancer Inst, 2000, 92(11): 874-897. ［19］ He J, Shi TY, Zhu ML, et al. Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis［J］. Int J Cancer, 2013, 133(8): 1765-1775. DOI: 10.1002/ijc.28089. ［20］ Janicijevi′c A, Sugasawa K, Shimizu Y, et al. DNA bending by the human damage recognition complex XPC-HR23B［J］. DNA Repair (Amst), 2003, 2(3): 325-336. ［21］ Tapias A, Auriol J, Forget D, et al. Ordered conformational changes in damaged DNA induced by nucleotide excision repair factors［J］. J Biol Chem, 2004, 279(18): 19074-19083. ［22］袁芃, 缪小平, 张雪梅, 等. 核苷酸切除修复系统基因遗传多态与晚期非小细胞肺癌患者铂类药物敏感性关系［J］. 癌症, 2005, 24(12): 1510-1513. ［23］ Francisco G, Menezes PR, Eluf-Neto J, et al. XPC polymorphisms play a role in tissue-specific carcinogenesis: a metaanalysis［J］. Eur J Hum Genet, 2008, 16(6): 724-734. DOI: 10.1038/ejhg.2008.6. ［24］ Blankenburg S, K-nig IR, Moessner R, et al. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a casecontrol study［J］. Carcinogenesis, 2005, 26(6): 1085-1090. ［25］郭炜, 周荣秒, 李琰, 等. XPC基因多态性与食管鳞状细胞癌、贲门腺癌的发病风险［J］. 肿瘤防治研究, 2007, 34(3): 209-213. ［26］ Jiang X, Zhou LT, Zhang SC, et al. XPC polymorphism increases risk of digestive system cancers: current evidence from a metaanalysis［J］. Chin J Cancer Res, 2012, 24(3): 181-189. DOI: 10.1007/s11670-012-0181-0. ［27］ Peng Q, Chen Z, Lu Y, et al. Current evidences on XPC polymorphisms and gastric cancer susceptibility: a meta-analysis［J］. Diagn Pathol, 2014, 9: 96. DOI: 10.1186/1746-1596-9-96.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[9]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[10]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.
[11]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682.
[13]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635.
[14]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[15]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728.